机构:[1]Chengdu Cancer Bioengineering Research Institute, 37 Twelve Bridge Road, Chengdu 610075, Sichuan, PR China[2]Chengdu Geimmica Scientific Ltd, Chengdu, Sichuan, PR China[3]Department of Oncology, Sichuan Academy of Medical Sciences,Chengdu, Sichuan, PR China四川省人民医院[4]Core Laboratory, Sichuan Academy of Medical Sciences, Chengdu, Sichuan, PR China四川省人民医院[5]Laboratory of Stem Cells and Regeneration Medicine, The Affiliated Hospital of Weifang Medical University, Weifang, Shandong,PR China
Background: The production of autoantibodies against tumour-associated antigens (TAAs) is believed to reflect greater immunologic reactivity in cancer patients and enhanced immune surveillance for cancer cells. Over the past few decades, a number of different TAAs and their corresponding autoantibodies have been investigated. However, positive frequency of autoantibody detection in cancer patients has been relatively low. Here we describe a novel TAA that was a fragment derived from human DNA-topoiomerase I and an autoantibody against the novel TAA with relatively high positive frequency in the sera of early-stage non-small-cell lung cancer (NSCLC), gastric cancer (GC), colorectal cancer (CRC) and oesophageal squamous cell carcinoma (ESCC). Methods: Serologic enzyme-linked immunosorbent assay (ELISA) and western blot were used to discover a novel TAA with a molecular weight of 48 kDa separated by ion exchange chromatography. Autoantibody ELISA, immnohistochemistry and immunofluorescent staining, recombinant protein cloning/expression and western blot were used to identify the novel TAA. The association of the autoantibody against the novel TAA with early-stage carcinoma was explored by screening 203 stage I/II patients and 170 stage III/IV patients with NSCLC, GC, CRC or ESCC. Results: We identified the novel TAA as a fragment derived from human DNA-topoiomerase I (TOP1). We found that the novel TAA induced specific autoantibodies with a high prevalence that ranged from 58 to 72% in some of the most common types of cancer. We observed that the immune response against the novel TAA was associated with early stage ESCC, GC, CRC and NSCLC. Conclusions: The findings in this study suggest that the autoantibody against the novel TAA may be a potential biomarker for use in the early detection and diagnosis of cancer.
基金:
Research and Development Program of the Chengdu Technology Bureau [KJXM20030826]
第一作者机构:[1]Chengdu Cancer Bioengineering Research Institute, 37 Twelve Bridge Road, Chengdu 610075, Sichuan, PR China[2]Chengdu Geimmica Scientific Ltd, Chengdu, Sichuan, PR China[3]Department of Oncology, Sichuan Academy of Medical Sciences,Chengdu, Sichuan, PR China
通讯作者:
通讯机构:[1]Chengdu Cancer Bioengineering Research Institute, 37 Twelve Bridge Road, Chengdu 610075, Sichuan, PR China[2]Chengdu Geimmica Scientific Ltd, Chengdu, Sichuan, PR China[3]Department of Oncology, Sichuan Academy of Medical Sciences,Chengdu, Sichuan, PR China
推荐引用方式(GB/T 7714):
Yie Shang-mian,Ye Shang-rong,Ma Xiao-li,et al.A protein fragment derived from DNA-topoisomerase I as a novel tumour-associated antigen for the detection of early stage carcinoma[J].BRITISH JOURNAL OF CANCER.2016,115(12):1555-1564.doi:10.1038/bjc.2016.369.
APA:
Yie, Shang-mian,Ye, Shang-rong,Ma, Xiao-li,Xie, Ke,Zhang, Jian-bo...&Zeng, Jie.(2016).A protein fragment derived from DNA-topoisomerase I as a novel tumour-associated antigen for the detection of early stage carcinoma.BRITISH JOURNAL OF CANCER,115,(12)
MLA:
Yie, Shang-mian,et al."A protein fragment derived from DNA-topoisomerase I as a novel tumour-associated antigen for the detection of early stage carcinoma".BRITISH JOURNAL OF CANCER 115..12(2016):1555-1564